Lab

People

Companies

Stories

Rapid Response

Rapid antibody development is urgently needed to tackle outbreaks of emerging infectious diseases. Creating therapeutics for these disease-causing agents typically requires years of clinical and regulatory assessment before they become available to patients. The Sasisekharan Lab at MIT and at SMART, Singapore has been actively exploring ways to condense drug development timelines by performing many of the necessary steps in parallel. With advanced instrumentation support from Agilent Technologies, our approach is to use the regulatory framework as a design constraint. In beginning with this framework in mind and working with regulators each step of the way, we can rapidly develop, produce, and evaluate antibody candidates for safety and efficacy in humans.

approach considers the regulatory framework as the driving design constraint, and then seeks to retool the traditional linear experimental approach to drug development in parallel manner. With this framework in mind and working with regulators each step of the way, we can rapidly develop, produce, and evaluate antibody candidates for safety and efficacy in humans.

This framework has led to biologics development (including GMP manufacturing and non-clinical studies) and first-in-human studies with unprecedented timelines. We moved from design to first-in-human infusion in 4 months for Zika virus, ~6 months for Yellow Fever virus, and most recently 4 months for SARS 2 (COVID19).

Rapid antibody development yields possible treatment for yellow fever

Hastening vaccines and treatments